Skip to main content
Midas Edge

Viridian Therapeutics, Inc.\DE

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

VRDN$30.86+2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share data)

Convertible Preferred Stock · Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Series A · Series B
Shares · Amount · Shares · Amount · Shares · Amount
Balance as of December 31, 2025134,864$61,18879,620$70,868101,826,500$1,018$1,927,104$447$(1,338,458)$722,167
Issuance of common stock upon exercises of stock options————424,64856,352——6,357
Issuance of common stock upon vesting of restricted stock units————206,9462(2)———
Share-based compensation expense——————13,390——13,390
Unrealized loss on available-for-sale securities———————(1,008)—(1,008)
Change in cumulative translation adjustment———————3—3
Net loss————————(104,901)(104,901)
Balance as of March 31, 2026134,864$61,18879,620$70,868102,458,094$1,025$1,946,844$(558)$(1,443,359)$636,008
Issuance of common stock upon conversion of convertible preferred stock(1,673)(756)(31,157)(33,276)2,188,7712234,010———
Issuance of common stock in an underwritten offering, net of issuance costs of $8,778————8,455,88385134,887——134,972
Issuance of common stock upon exercises of stock options————41,646—577——577
Issuance of common stock under employee stock purchase plan————92,842—1,270——1,270
Issuance of common stock upon vesting of restricted stock units————982—————
Share-based compensation expense——————16,984——16,984
Unrealized loss on available-for-sale securities———————(598)—(598)
Change in cumulative translation adjustment———————3—3
Net loss————————(127,119)(127,119)
Balance as of June 30, 2026133,191$60,43248,463$37,592113,238,218$1,132$2,134,572$(1,153)$(1,570,478)$662,097

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share data)

Convertible Preferred Stock · Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Series A · Series B
Shares · Amount · Shares · Amount · Shares · Amount
Balance as of December 31, 2024134,864$61,188145,160$127,69780,994,046$810$1,477,811$(10)$(995,857)$671,639
Issuance of common stock in at-the-market offerings, net of issuance costs of $149————245,38834,792——4,795
Issuance of common stock upon exercises of warrants————115,14611,617——1,618
Issuance of common stock upon exercises of stock options————185,42622,295——2,297
Issuance of common stock under employee stock purchase plan————41,106—561——561
Issuance of common stock upon vesting of restricted stock units————8,315—————
Share-based compensation expense——————10,220——10,220
Unrealized gain on available-for-sale securities———————255—255
Net loss————————(86,912)(86,912)
Balance as of March 31, 2025134,864$61,188145,160$127,69781,589,427$816$1,497,296$245$(1,082,769)$604,473
Issuance of common stock upon exercises of stock options————61,5271762——763
Issuance of common stock upon vesting of restricted stock units————232—————
Share-based compensation expense——————10,844——10,844
Unrealized loss on available-for-sale securities———————(176)—(176)
Net loss————————(100,735)(100,735)
Balance as of June 30, 2025134,864$61,188145,160$127,69781,651,186$817$1,508,902$69$(1,183,504)$515,169
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.